华北制药
(600812)
| 流通市值：84.24亿 | | | 总市值：84.24亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,557,512,113.04 | 10,120,201,384.84 | 7,974,681,092.8 | 5,233,404,242.63 |
| 营业收入 | 2,557,512,113.04 | 10,120,201,384.84 | 7,974,681,092.8 | 5,233,404,242.63 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 2,492,470,540.38 | 10,043,246,697.97 | 7,859,360,976.38 | 5,158,617,183.57 |
| 营业成本 | 1,775,121,974.03 | 6,883,613,724.28 | 5,444,085,215.5 | 3,518,377,901.59 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 25,024,982.02 | 104,230,534.59 | 78,728,681.44 | 61,495,324.98 |
| 销售费用 | 367,272,830.02 | 1,655,213,088.21 | 1,343,209,984.65 | 894,897,341.35 |
| 管理费用 | 133,918,389.32 | 630,241,751.54 | 435,695,557.53 | 304,314,470.69 |
| 研发费用 | 76,220,731.53 | 297,200,481.64 | 205,355,087.05 | 141,925,060.43 |
| 财务费用 | 114,911,633.46 | 472,747,117.71 | 352,286,450.21 | 237,607,084.53 |
| 其中:利息费用 | 120,542,713.06 | 501,895,716.87 | 379,707,560.94 | 260,426,565.13 |
| 其中:利息收入 | 6,378,070.44 | 27,666,240.15 | 21,586,077.55 | 14,432,146.48 |
| 加:投资收益 | 7,712,725.48 | 46,851,144.77 | 34,161,236.66 | 23,768,373.32 |
| 资产处置收益 | - | 755,820.22 | 652,824.1 | 466,650.78 |
| 资产减值损失(新) | -3,525,543.89 | -14,475,002.15 | -22,575,448.62 | -14,906,253.89 |
| 信用减值损失(新) | -19,006,216.68 | -670,157.34 | -38,425,273.5 | -20,754,390.73 |
| 其他收益 | 7,455,958.3 | 47,036,729.02 | 31,858,969.98 | 19,157,248.13 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 57,678,495.87 | 156,453,221.39 | 120,992,425.04 | 82,518,686.67 |
| 加:营业外收入 | 546,863.15 | 10,212,489.78 | 7,148,322.61 | 5,458,100.55 |
| 减:营业外支出 | 200,705.06 | 8,130,025.38 | 1,056,378.17 | 678,789.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 58,024,653.96 | 158,535,685.79 | 127,084,369.48 | 87,297,997.87 |
| 减:所得税费用 | 25,230,603.65 | 109,147,808.57 | 76,701,683.06 | 44,494,439.85 |
| 六、净利润 | 32,794,050.31 | 49,387,877.22 | 50,382,686.42 | 42,803,558.02 |
| 持续经营净利润 | 32,794,050.31 | 49,387,877.22 | 50,382,686.42 | 42,803,558.02 |
| 归属于母公司股东的净利润 | 18,152,447.09 | 4,890,347.22 | 27,973,093.7 | 26,545,580.14 |
| 少数股东损益 | 14,641,603.22 | 44,497,530 | 22,409,592.72 | 16,257,977.88 |
| (一)基本每股收益 | 0.01 | 0 | 0.02 | 0.02 |
| (二)稀释每股收益 | 0.01 | 0 | 0.02 | 0.02 |
| 八、其他综合收益 | 38,463.8 | -2,004,968.68 | 1,609,162.75 | 1,696,264.67 |
| 归属于母公司股东的其他综合收益 | 38,463.8 | -2,004,968.68 | 1,609,162.75 | 1,696,264.67 |
| 九、综合收益总额 | 32,832,514.11 | 47,382,908.54 | 51,991,849.17 | 44,499,822.69 |
| 归属于母公司股东的综合收益总额 | 18,190,910.89 | 2,885,378.54 | 29,582,256.45 | 28,241,844.81 |
| 归属于少数股东的综合收益总额 | 14,641,603.22 | 44,497,530 | 22,409,592.72 | 16,257,977.88 |
| 公告日期 | 2024-04-26 | 2024-03-30 | 2023-10-27 | 2023-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |